 Immunotherapy, Adoptive
"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 | | 1994 | 0 | 2 | 2 | | 1997 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 3 | 3 | | 2003 | 2 | 4 | 6 | | 2004 | 2 | 4 | 6 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 2 | 4 | | 2007 | 1 | 1 | 2 | | 2008 | 1 | 2 | 3 | | 2010 | 4 | 2 | 6 | | 2011 | 1 | 1 | 2 | | 2012 | 3 | 2 | 5 | | 2013 | 5 | 0 | 5 | | 2014 | 3 | 1 | 4 | | 2015 | 4 | 2 | 6 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 0 | 1 | | 2018 | 3 | 1 | 4 | | 2019 | 5 | 0 | 5 | | 2020 | 3 | 1 | 4 | | 2021 | 11 | 2 | 13 | | 2022 | 0 | 8 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Okamura K, Nagayama S, Tate T, Chan HT, Kiyotani K, Nakamura Y. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. J Transl Med. 2022 May 23; 20(1):241.
-
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806.
-
Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 04; 28(4):735-742.
-
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022 04; 28(4):713-723.
-
Cohen AD, Parekh S, Santomasso BD, Gállego Pérez-Larraya J, van de Donk NWCJ, Arnulf B, Mateos MV, Lendvai N, Jackson CC, De Braganca KC, Schecter JM, Marquez L, Lee E, Cornax I, Zudaire E, Li C, Olyslager Y, Madduri D, Varsos H, Pacaud L, Akram M, Geng D, Jakubowiak A, Einsele H, Jagannath S. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022 02 24; 12(2):32.
-
Khanna S, Mackin AG, Dao DT, Komati R, Morocco PC, LaBelle JL, Shah HA, Blair MP. Exudative Retinal Detachment Following Chimeric Antigen Receptor T-Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Ophthalmic Surg Lasers Imaging Retina. 2022 02; 53(2):113-115.
-
Ying L, Yazdani M, Koya R, Zhao R. Engineering tumor stromal mechanics for improved T cell therapy. Biochim Biophys Acta Gen Subj. 2022 04; 1866(4):130095.
-
Matsuzaki J, Lele S, Odunsi K, Tsuji T. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer. Oncoimmunology. 2022; 11(1):2020983.
-
Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 02; 28(2):325-332.
-
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 02 17; 386(7):640-654.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|